BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 06:29 (401 d 04:04 ago) – Posting: # 21417
Views: 2,203

» I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.

Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at [email protected]
Similar approach (Don't ask how I know :))

J

Complete thread:

Activity
 Admin contact
21,523 posts in 4,499 threads, 1,523 registered users;
online 18 (0 registered, 18 guests [including 3 identified bots]).
Forum time: Wednesday 10:33 CEST (Europe/Vienna)

Don’t undertake a project
unless it’s manifestly important
and nearly impossible.    Edwin H. Land

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5